[{"indications": "Indications\u00a0severe pain requiring opioid\r\nanalgesia", "name": "OXYCODONE WITH NALOXONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.2 Opioid analgesics", "OXYCODONE WITH NALOXONE"], "cautions": "Cautions\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nOpioids should be used with caution in patients with impaired respiratory function (avoid in chronic obstructive pulmonary disease) and asthma (avoid during an acute attack), hypotension, urethral stenosis, shock, myasthenia gravis, prostatic hypertrophy, obstructive or inflammatory bowel disorders, diseases of the biliary tract, and convulsive disorders. A reduced dose is recommended in elderly or debilitated patients, in hypothyroidism, and in adrenocortical insufficiency. Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence. Avoid abrupt withdrawal after long-term treatment. Transdermal preparations (fentanyl or buprenorphine patches) are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Interactions: Appendix 1 (opioid analgesics; important: special hazard with pethidine and possibly other opioids and MAOIs). and under %s\n(From OXYCODONE HYDROCHLORIDE: British National Formulary)\nOXYCODONE HYDROCHLORIDE; also hypertension", "side-effects": "Side-effects\u00a0see under Oxycodone Hydrochloride; withdrawal symptoms\r\nmay be provoked in patients switching from other chronic high-dose\r\nopioid treatment; also weight changes, angina, hypertension, rhinorrhoea,\r\nmalaise; rarely yawning", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/202521.htm", "doses": ["See under preparations", "adult over 18 years not\r\ncurrently treated with opioid analgesics, initially 10\u00a0mg/5\u00a0mg every\r\n12 hours, increased according to response; patients already receiving\r\nopioid analgesics can start with a higher dose of Targinact\u00ae; max. Targinact\u00ae 40\u00a0mg/20\u00a0mg every 12 hours", "Supplemental modified-release oxycodone (without\r\nnaloxone) can be prescribed for patients who need higher doses\u2014consult\r\nproduct literature"], "pregnancy": "Pregnancy\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nHepatic impairment\u00a0Opioid analgesics may precipitate coma in patients with hepatic impairment; avoid use or reduce dose.Renal impairment\u00a0The effects of opioid analgesia are increased and prolonged and there is increased cerebral sensitivity when patients with renal impairment are treated with opioid analgesics; avoid use or reduce dose.Pregnancy\u00a0Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour. "}, {"indications": "Indications\u00a0moderate to severe pain in patients with cancer;\r\npostoperative pain; severe pain", "name": "OXYCODONE HYDROCHLORIDE Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.2 Opioid analgesics", "OXYCODONE HYDROCHLORIDE", "Modified release"], "cautions": "Cautions\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nCautions\u00a0Opioids should be used with caution in patients with impaired respiratory function (avoid in chronic obstructive pulmonary disease) and asthma (avoid during an acute attack), hypotension, urethral stenosis, shock, myasthenia gravis, prostatic hypertrophy, obstructive or inflammatory bowel disorders, diseases of the biliary tract, and convulsive disorders. A reduced dose is recommended in elderly or debilitated patients, in hypothyroidism, and in adrenocortical insufficiency. Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence. Avoid abrupt withdrawal after long-term treatment. Transdermal preparations (fentanyl or buprenorphine patches) are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Interactions: Appendix 1 (opioid analgesics; important: special hazard with pethidine and possibly other opioids and MAOIs).Palliative care\u00a0In the control of pain in terminal illness, the cautions listed above should not necessarily be a deterrent to the use of opioid analgesics.; also toxic psychosis; pancreatitis", "side-effects": "Side-effects\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nSide-effects\u00a0Opioid analgesics share many side-effects, although qualitative and quantitative differences exist. The most common side-effects include nausea and vomiting (particularly in initial stages), constipation, dry mouth, and biliary spasm; larger doses produce muscle rigidity, hypotension, and respiratory depression (for reversal of opioid-induced respiratory depression, see section 15.1.7). Other common side-effects of opioid analgesics include bradycardia, tachycardia, palpitation, oedema, postural hypotension, hallucinations, vertigo, euphoria, dysphoria, mood changes, dependence, dizziness, confusion, drowsiness, sleep disturbances, headache, sexual dysfunction, difficulty with micturition, urinary retention, ureteric spasm, miosis, visual disturbances, sweating, flushing, rash, urticaria, and pruritus. Overdosage: see Emergency Treatment of Poisoning.Long-term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both men and women. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility, depression, and erectile dysfunction. Long-term use of opioid analgesics has also been associated with a state of abnormal pain sensitivity (hyperalgesia). Pain associated with hyperalgesia is usually distinct from pain associated with disease progression or breakthrough pain, and is often more diffuse and less defined. Treatment of hyperalgesia involves reducing the dose of opioid medication or switching therapy; cases of suspected hyperalgesia should be referred to a specialist pain team.; also\r\ndiarrhoea, abdominal pain, anorexia, dyspepsia; bronchospasm, dyspnoea,\r\nimpaired cough reflex; asthenia, anxiety; chills; less commonly paralytic ileus, cholestasis, gastritis, flatulence, dysphagia,\r\ntaste disturbance, belching, hiccups, vasodilatation, supraventricular\r\ntachycardia, syncope, amnesia, hypoaesthesia, restlessness, seizures,\r\nhypotonia, paraesthesia, disorientation, malaise, agitation, speech\r\ndisorder, tremor, pyrexia, amenorrhoea, thirst, dehydration, muscle\r\nfasciculation, and dry skin", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/85409.htm", "doses": ["By mouth, initially 5\u00a0mg every 4\u20136 hours,\r\nincreased if necessary according to severity of pain, usual max. 400\u00a0mg\r\ndaily, but some patients may require higher doses; child under 18 years see BNF for Children", "By slow intravenous injection, 1\u201310\u00a0mg every\r\n4 hours when necessary; child under\r\n18 years, not recommended", "By intravenous infusion, initially 2\u00a0mg/hour,\r\nadjusted according to response; child under 18 years not recommended", "By subcutaneous injection, initially 5\u00a0mg every\r\n4 hours when necessary; child under\r\n18 years not recommended", "By subcutaneous infusion, initially 7.5\u00a0mg/24\r\nhours adjusted according to response; child under 18 years not recommended", "Patient controlled analgesia (PCA), consult hospital protocols", "2\u00a0mg oral oxycodone is\r\napproximately equivalent to 1\u00a0mg parenteral oxycodone", "Name[OxyContin\u00ae (Napp) ] Tablets, f/c, m/r, oxycodone\r\nhydrochloride 5\u00a0mg (blue), net price 28-tab pack = \u00a312.46;\r\n10\u00a0mg (white), 56-tab pack = \u00a324.91; 15\u00a0mg (grey), 56-tab pack = \u00a337.41;\r\n20\u00a0mg (pink), 56-tab pack = \u00a349.82; 30\u00a0mg (brown), 56-tab pack = \u00a374.81;\r\n40\u00a0mg (yellow), 56-tab pack = \u00a399.66; 60\u00a0mg (red), 56-tab pack = \u00a3149.66;\r\n80\u00a0mg (green), 56-tab pack = \u00a3199.33; 120\u00a0mg (purple), 56-tab pack\r\n= \u00a3299.31. \r\n    Label:\r\n    2, 25Dose\u00a0initially, 10\u00a0mg every 12 hours, increased if necessary\r\naccording to severity of pain, usual max. 200\u00a0mg every 12 hours, but\r\nsome patients may require higher doses; child under 18 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nHepatic impairment\u00a0Opioid analgesics may precipitate coma in patients with hepatic impairment; avoid use or reduce dose.Renal impairment\u00a0The effects of opioid analgesia are increased and prolonged and there is increased cerebral sensitivity when patients with renal impairment are treated with opioid analgesics; avoid use or reduce dose.Pregnancy\u00a0Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour."}, {"indications": "Indications\u00a0moderate to severe pain in patients with cancer;\r\npostoperative pain; severe pain", "name": "OXYCODONE HYDROCHLORIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.2 Opioid analgesics", "OXYCODONE HYDROCHLORIDE"], "cautions": "Cautions\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nCautions\u00a0Opioids should be used with caution in patients with impaired respiratory function (avoid in chronic obstructive pulmonary disease) and asthma (avoid during an acute attack), hypotension, urethral stenosis, shock, myasthenia gravis, prostatic hypertrophy, obstructive or inflammatory bowel disorders, diseases of the biliary tract, and convulsive disorders. A reduced dose is recommended in elderly or debilitated patients, in hypothyroidism, and in adrenocortical insufficiency. Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence. Avoid abrupt withdrawal after long-term treatment. Transdermal preparations (fentanyl or buprenorphine patches) are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Interactions: Appendix 1 (opioid analgesics; important: special hazard with pethidine and possibly other opioids and MAOIs).Palliative care\u00a0In the control of pain in terminal illness, the cautions listed above should not necessarily be a deterrent to the use of opioid analgesics.; also toxic psychosis; pancreatitis", "side-effects": "Side-effects\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nSide-effects\u00a0Opioid analgesics share many side-effects, although qualitative and quantitative differences exist. The most common side-effects include nausea and vomiting (particularly in initial stages), constipation, dry mouth, and biliary spasm; larger doses produce muscle rigidity, hypotension, and respiratory depression (for reversal of opioid-induced respiratory depression, see section 15.1.7). Other common side-effects of opioid analgesics include bradycardia, tachycardia, palpitation, oedema, postural hypotension, hallucinations, vertigo, euphoria, dysphoria, mood changes, dependence, dizziness, confusion, drowsiness, sleep disturbances, headache, sexual dysfunction, difficulty with micturition, urinary retention, ureteric spasm, miosis, visual disturbances, sweating, flushing, rash, urticaria, and pruritus. Overdosage: see Emergency Treatment of Poisoning.Long-term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both men and women. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility, depression, and erectile dysfunction. Long-term use of opioid analgesics has also been associated with a state of abnormal pain sensitivity (hyperalgesia). Pain associated with hyperalgesia is usually distinct from pain associated with disease progression or breakthrough pain, and is often more diffuse and less defined. Treatment of hyperalgesia involves reducing the dose of opioid medication or switching therapy; cases of suspected hyperalgesia should be referred to a specialist pain team.; also\r\ndiarrhoea, abdominal pain, anorexia, dyspepsia; bronchospasm, dyspnoea,\r\nimpaired cough reflex; asthenia, anxiety; chills; less commonly paralytic ileus, cholestasis, gastritis, flatulence, dysphagia,\r\ntaste disturbance, belching, hiccups, vasodilatation, supraventricular\r\ntachycardia, syncope, amnesia, hypoaesthesia, restlessness, seizures,\r\nhypotonia, paraesthesia, disorientation, malaise, agitation, speech\r\ndisorder, tremor, pyrexia, amenorrhoea, thirst, dehydration, muscle\r\nfasciculation, and dry skin", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/85407.htm", "doses": ["By mouth, initially 5\u00a0mg every 4\u20136 hours,\r\nincreased if necessary according to severity of pain, usual max. 400\u00a0mg\r\ndaily, but some patients may require higher doses; child under 18 years see BNF for Children", "By slow intravenous injection, 1\u201310\u00a0mg every\r\n4 hours when necessary; child under\r\n18 years, not recommended", "By intravenous infusion, initially 2\u00a0mg/hour,\r\nadjusted according to response; child under 18 years not recommended", "By subcutaneous injection, initially 5\u00a0mg every\r\n4 hours when necessary; child under\r\n18 years not recommended", "By subcutaneous infusion, initially 7.5\u00a0mg/24\r\nhours adjusted according to response; child under 18 years not recommended", "Patient controlled analgesia (PCA), consult hospital protocols", "2\u00a0mg oral oxycodone is\r\napproximately equivalent to 1\u00a0mg parenteral oxycodone"], "pregnancy": "Pregnancy\u00a0\n(From 4.7.2 Opioid analgesics: British National Formulary)\nHepatic impairment\u00a0Opioid analgesics may precipitate coma in patients with hepatic impairment; avoid use or reduce dose.Renal impairment\u00a0The effects of opioid analgesia are increased and prolonged and there is increased cerebral sensitivity when patients with renal impairment are treated with opioid analgesics; avoid use or reduce dose.Pregnancy\u00a0Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour."}]